1999
DOI: 10.3810/pgm.1999.02.560
|View full text |Cite
|
Sign up to set email alerts
|

Clinically significant drug interactions

Abstract: Ironically, pharmacotherapy can harm the very patients it is intended to help if clinically significant drug interactions occur. However, knowledge of the role of the hepatic cytochrome P-450 isoenzyme system in drug interactions has expanded greatly with advances in gene-mapping technologies, and an understanding of the system can aid physicians in preventing or minimizing complications from drug interactions mediated through that system. The authors summarize the role of important isoenzymes and drugs that i… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
15
0
4

Year Published

2001
2001
2018
2018

Publication Types

Select...
6
4

Relationship

0
10

Authors

Journals

citations
Cited by 36 publications
(19 citation statements)
references
References 14 publications
0
15
0
4
Order By: Relevance
“…In general, DDIs usually have a specific time course i.e. onset and duration and this makes them more predictable and preventable than ADRs 20. This finding suggests that one should be careful while prescribing drugs that can cause delayed type of DDIs.…”
Section: Discussionmentioning
confidence: 99%
“…In general, DDIs usually have a specific time course i.e. onset and duration and this makes them more predictable and preventable than ADRs 20. This finding suggests that one should be careful while prescribing drugs that can cause delayed type of DDIs.…”
Section: Discussionmentioning
confidence: 99%
“…Inhibition Inhibition of CYP enzymes is the most common mechanism that produces serious and potentially life-threatening drug interactions (Johnson et al, 1999). Most enzyme inhibitors act specifically on individual CYP enzymes, so a drug inhibiting CYP2A6 may have no effect on CYP2C19.…”
Section: Cyp Enzyme Induction and Inhibitionmentioning
confidence: 99%
“…Interactions involving the CYP450 enzymes are often due to either inhibition of an isoenzyme, leading to increased blood or tissue concentrations of the substrate, or induction of an isoenzyme, causing enhanced metabolism and lower substrate concentrations (Delafuente, 2003:137). According to Johnson et al (1999) enzyme inhibition is the mechanism most often responsible for life-threatening interactions. 32 Such interactions have been observed when zalcitabine is combined with stavudine or didanosine producing severe peripheral neuropathy, pancreatitis, and lactic acidosis (Simpson & Tagliati, 1995).…”
Section: Cytochrome P450 Isoenzymementioning
confidence: 99%